Hemophilia without prophylaxis: Assessment of joint range of

Por um escritor misterioso
Last updated 17 junho 2024
Hemophilia without prophylaxis: Assessment of joint range of
Hemophilia without prophylaxis: Assessment of joint range of
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial - The Lancet
Hemophilia without prophylaxis: Assessment of joint range of
Hemophilia A and B: An Overview
Hemophilia without prophylaxis: Assessment of joint range of
Advances in Hemophilia A Management - Advances in Pediatrics
Hemophilia without prophylaxis: Assessment of joint range of
Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort - The Lancet Haematology
Hemophilia without prophylaxis: Assessment of joint range of
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A
Hemophilia without prophylaxis: Assessment of joint range of
Severe Hem A Patients Showing Bleeds, Physical Limits With Prophylaxis
Hemophilia without prophylaxis: Assessment of joint range of
Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
Hemophilia without prophylaxis: Assessment of joint range of
Clinical outcome and incidence of inhibitor development in severe hemophilia patients receiving low-dose prophylaxis: a 3-year follow-up study in Senegal, West Africa
Hemophilia without prophylaxis: Assessment of joint range of
Resolution of Target Joints (TJs) in Children with Severe Haemophilia A (HA) Treated with Turoctocog Alfa Pegol (N8-GP) Prophylaxis: Results from the Pathfinder 5 Trial - ISTH Congress Abstracts

© 2014-2024 miaad.org. All rights reserved.